Senator Rick Scott (R-FL) is pressing the Trump administration to take immediate action to secure the U.S. pharmaceutical supply chain, calling for the application of Section 232 tariffs on imported generic drugs.
In a letter sent Friday to Commerce Secretary Howard Lutnick and U.S. Trade Representative Ambassador Jamieson Greer, Senator Scott thanked the officials for their work on the “America First agenda” and urged them to accelerate efforts in the ongoing Section 232 investigation into the national security implications of pharmaceutical imports.
Senator Scott, who chairs the Senate Special Committee on Aging, highlighted the “dangerous overreliance” on foreign adversaries, particularly Communist China, for generic medicines. The letter asserts that generics make up 90% of U.S. prescriptions, yet an alarming 70–80% of these use Active Pharmaceutical Ingredients (APIs) sourced from China and India.
The Senator detailed the national security and public health vulnerabilities posed by this dependency, noting that approximately 83% of the top 100 generic drugs consumed by Americans have no U.S.-based source for their APIs. He cited risks such as drug shortages and quality control concerns, pointing to a study that found foreign generics were associated with a 54% greater risk of serious adverse events compared with domestically made equivalents.
“We’ve also seen China place export restrictions on rare earth elements over trade negotiations before, and there’s no reason they can’t do the same for pharmaceuticals,” Scott wrote, emphasizing the clear vulnerability to the nation’s health.
To combat this, Senator Scott requested the immediate application of Section 232 tariffs on foreign generic medicines (including APIs and key starting materials) or, at minimum, a public commitment to a phased-in tariff regime within 12 months. He stressed that a domestic production base is viable, with 85% of hospital pharmacists reportedly willing to pay more for U.S.-made generics.
This letter follows previous efforts by Senator Scott to sound the alarm on the issue, including a recent Senate Special Committee on Aging hearing and a separate letter to the Food and Drug Administration (FDA) Commissioner on the oversight of foreign drug manufacturing.
RELATED: Op-Ed: It’s Time To Shut The Door On Dangerous Foreign Drugs
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.
